Inbound open innovation for pharmaceutical markets: a case study of an anti-diabetic drug in-licensing decision

被引:15
|
作者
Wu, Allan Ya-Huan [1 ]
Little, Victoria Janine [2 ]
Low, Brian [3 ]
机构
[1] Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand
[2] Univ Auckland, Dept Mkt, Auckland 1, New Zealand
[3] Monash Univ Malaysia, Dept Mkt, Kuala Lumpur, Malaysia
关键词
Decision-making; New product development; Pharmaceuticals industry; Technological innovation; Marketing management; Knowledge management; PRODUCT DEVELOPMENT; ABSORPTIVE-CAPACITY; FIRM RESOURCES; TECHNOLOGY; MODEL; VIEW; PERSPECTIVE; KNOWLEDGE; FRAMEWORK; BEHAVIOR;
D O I
10.1108/JBIM-10-2013-0236
中图分类号
F [经济];
学科分类号
02 ;
摘要
Purpose - This paper aims to increase understanding of how firms can more effectively identify valuable and profitable innovations in the pharmaceutical industry and to identify the issues and challenges posed by current managerial decision-making practices. Design/methodology/approach - A case study of a single project is presented: a drug in-licensing decision made by a team of three managers in a large Australian pharmaceutical firm. Using participant-observation, interviews and archival analysis, the authors followed the managers as they identified and evaluated 122 late-stage anti-diabetic drug variants for further development. Findings - The managers used decision heuristics to arrive at a short list of three drugs from a choice set of 122. While the process was ostensibly rational and systematic, there was evidence of data quality issues, misleading mental models and cognitive bias. The authors concluded a high probability of accepting a poor candidate or rejecting a stronger candidate (i.e. making Type I and II errors). Research limitations/implications - This paper focuses on initial market and technology evaluation stage only (i.e. not commercialization) and is a single case study design; therefore, care should be taken in generalizing to other decisions or other contexts. This paper highlights the need for further research integrating organizational decision-making and open innovation from a multi-disciplinary perspective. Practical/implications - This paper raises awareness of potential decision-making pitfalls and includes a detailed audit framework to support improved managerial decision processes and double rather than single loop learning. Social/implications - The findings support better decision-making and therefore supports higher quality drug selection and development, leading to improved population health outcomes. Originality/value - Multi-disciplinary, draws attention of marketing and new product development scholars to open innovation research. It adds to knowledge about open innovation practices at the project level. It also provides an extended model of market opportunity analysis for high technology markets.
引用
收藏
页码:205 / 218
页数:14
相关论文
共 37 条
  • [31] Anti-Diabetic Therapies and Cancer Risk among Type 2 Diabetes Patients in Taiwan - A Nationwide Nested Case-Control Study
    Wu, Li-Chiu
    Chang, Chia-Hsuin
    Chunag, Lee-Ming
    Lai, Mei-Shu
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S290 - S290
  • [32] Final Results of a Large Multi-National Postmarketing Safety Study Evaluating Use of the Oral Anti-Diabetic Drug Saxagliptin and Risk of Five Outcomes
    Lo Re, Vincent, III
    Carbonari, Dena M.
    Newcomb, Craig W.
    Saine, M. Elle
    Roy, Jason A.
    Cardillo, Serena
    Haynes, Kevin
    Kimmel, Stephen E.
    Reese, Peter P.
    Margolis, David J.
    Apter, Andrea J.
    Reddy, K. Rajender
    Bhullar, Harshvinder
    Gallagher, Arlene M.
    Esposito, Daina B.
    Strom, Brian L.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 245 - 246
  • [33] Anti-diabetic medications and the risk for colorectal cancer in adult type 2 diabetes: A population-based nested case-control study
    Shin, Cheol Min
    Kim, Nayoung
    Han, Kyungdo
    Jung, Jin Hyung
    Yoon, Hyuk
    Park, Young Soo
    Lee, Dong Ho
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 514 - 514
  • [34] Are adverse drug reactions to anti-diabetic drugs more common in patients whose treatment do not adhere to diabetes management clinical guidelines? Comments on a study report
    Rezaie, Zahra
    Taghizadeh-Ghehi, Maryam
    Jafarzadeh Kohneloo, Aarefeh
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (09) : 1429 - 1430
  • [35] Are adverse drug reactions to anti-diabetic drugs more common in patients whose treatment do not adhere to diabetes management clinical guidelines? Comments on a study report
    Zahra Rezaie
    Maryam Taghizadeh-Ghehi
    Aarefeh Jafarzadeh Kohneloo
    [J]. European Journal of Clinical Pharmacology, 2021, 77 : 1429 - 1430
  • [36] Adverse drug reactions to anti-diabetic drugs are commonest in patients whose treatment do not adhere to diabetes management clinical guidelines: cross-sectional study in a tertiary care service in sub-Saharan Africa
    Agnes Elangwe
    Jean-Claude Katte
    Donald Tchapmi
    Albert Figueras
    Jean Claude Mbanya
    [J]. European Journal of Clinical Pharmacology, 2020, 76 : 1601 - 1605
  • [37] Adverse drug reactions to anti-diabetic drugs are commonest in patients whose treatment do not adhere to diabetes management clinical guidelines: cross-sectional study in a tertiary care service in sub-Saharan Africa
    Elangwe, Agnes
    Katte, Jean-Claude
    Tchapmi, Donald
    Figueras, Albert
    Mbanya, Jean Claude
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (11) : 1601 - 1605